TNFRSF10B (1D8) Monoclonal Antibody

$Lane 1: HL-60 Cells; Probed with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: HL-60 Cells; Probed with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Colon Carcinoma tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining.$

Paraformaldehyde-fixed and paraffin-embedded Human Colon Carcinoma tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining.

$Paraformaldehyde-fixed and paraffin-embedded Human Placenta tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Placenta tissue incubated with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Flow cytometric analysis of SW480 cells with TNFRSF10B (1D8) Monoclonal Antibody (bsm-54027R) at 1:100 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

Applications

WB
FCM
IHC-P
IF(IHC-P)
IP

Reactivity

Human

Overview
Catalog #	bsm-54027R
Product Name	TNFRSF10B (1D8) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(IHC-P), IP
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human DR5 aa 200 to the C-terminus
Clonality	Monoclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	8795
Swiss Prot	O14763
Synonyms	Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2, CD262, TNFRSF10B, DR5, KILLER, TRAILR2, TRICK2, ZTNFR9
Background	Tumor necrosis factor (TNF) is a pleiotropic cytokine whose function is mediated by two distinct cell surface receptors, designated TNF-R1 and TNF-R2, which are expressed on most cell types. TNF function is primarily mediated through TNF-R1 signaling. Both receptors belong to the growing TNF receptor superfamily which includes FAS antigen and CD40. TNF-R1 contains a cytoplasmic motif, termed the "death domain," that has been found to be necessary for the transduction of the apoptotic signal. The death domain is also found in several other receptors, including FAS, DR2 (or TRUNDD), DR3 (Death Receptor 3), DR4 and DR5. TRUNDD, DR4 and DR5 are receptors for the apoptosis-inducing cytokine TRAIL. A non-death domain-containing receptor, designated decoy receptor (DcR1 or TRID), also specifically associates with TRAIL and may play a role in cellular resistance to apoptotic stimuli.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IP	1-2ug